FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Tryp Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Tryp Therapeutics Inc. (TRYP.CN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTRYP.CN
TRYP.CN
Tryp Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TRYP.CN
Home🔹Stocks🔹Tryp Therapeutics Inc.

Tryp Therapeutics Inc.

TRYP.CN•CNQ

Tryp Therapeutics Inc.

TRYP.CN•CNQ
Market cap
$5.79M
Sentiment

Your view on TRYP.CN

Mkt Cap
$5.79M
Sentiment
Your view
TRYP.CN
Tryp Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TRYP.CN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Tryp Therapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jason Carroll
Headquarters
CA
Industry
Biotechnology
Sector
Healthcare
CEO
Jason Carroll
Headquarters
CA
Description

Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News